Fig. 6
From: Rational design of a triple-type human papillomavirus vaccine by compromising viral-type specificity
Immunogenicity of triple-type chimeric HPV33/52/58 VLPs in Cynomolgus Macaques. a Neutralization titers against PsV33, PsV52 and PsV58, respectively, from the immune sera in monkeys (n = 4) collected two weeks after the second immunization (immunization at weeks 0 and 8 with 5 μg per dose of aluminum adjuvant-containing chimeric H58-33BC-52HI or WT VLPs). Each symbol represents one monkey. Statistical significance was assessed by one-way ANOVA, **P < 0.01; ***P < 0.001; ****P < 0.0001. b Kinetics of serum neutralization titers in monkeys after immunization with the chimeric or WT VLPs. Immune sera were collected weekly after immunization, and serum neutralization titers were determined and plotted. The dotted line indicates the limit of detection for the assay. Non-neutralizing sera were assigned a value of half of the limit of detection for visualization. All the neutralizing titers were calculated to express the mean value with SD
